The evaluation of Fas/Fas ligand system in renal cell carcinoma - The effect of preoperative interferon-α therapy

Japanese Journal of Urology

Volumn 90, Issue 10, 1999, Pages 826-832

  Sejima, Takehiro ^a   Miyagawa, Ikuo ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Apoptosis; Interferon ; Renal cell carcinoma

Indexed keywords

ALPHA INTERFERON; FAS ANTIGEN; POLYCLONAL ANTIBODY;

ADULT; AGED; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER CELL; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MALE; PREOPERATIVE TREATMENT; TREATMENT OUTCOME;

EID: 0032723095     PISSN: 00215287     EISSN: None     Source Type: Journal    
DOI: 10.5980/jpnjurol1989.90.826     Document Type: Article

References (19)

1. Yonehara, S., Ishii, A. and Yonehara, M. : A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J.Exp, Med., 169, 1747-1756, 1989.
2. 2+ -independent T cell-mediated cytotoxiciiy. J.Exp. Med., 177, 195-200, 1993.
3. Suda, T., Takahashi, T., Golstein, P. and Nagata, S. : Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell. 75, 1169-1178, 1993.
4. Thompson, C.B. : Apoptosis in the pathogenesis and treatment of disease. Science. 267, 1456-1462, 1995
5. Horoszewicz, J.S. and Murphy, G.P. : An assessment of the current use of human interferons in therapy of uroiogical cancers. J.Urol., 142, 1173-1180, 1989.
6. Kägi, D. : Fas and perform pathways as major mechanisms of T cell-mediated cytotoxicity. Nature. 265, 528-530, 1994.
7. Lowin, B., Hahne, M., Mattmann, C. and Tschopp, J. : Cytolytic T-cell cytotoxicity is mediated through perform and Fas lytic pathways. Nature, 370, 650-652, 1994.
8. Inoue, M., Yano, H. and Kojiro, M. : Expression of Fas and anti-Fas-mediated apoptosis in human renal cell carcinoma, Int. J.Oncol., 9, 49-56, 1996.
9. Nonomura, N., Miki, T., Yokoyama, M., Imazu, T., Takada, T., Takeuchi, S. Kanno, N., Nishimura, K., Kojima, Y. and Okuyama, A. : Fas/APO-1-mediated apoptosis of human renal cell carcinoma. Biochem, Bioph. Res. Co., 229, 945-951, 1996.
10. Horie, S., Kano, M., Higashihara, E., Moriyama, N., Tanaka, E., Hirose, A., Kakizoe, T. and Kawabe, K. : Expression of Fas in renal cell carcinoma. Jpn. J. Clin. Oncol., 27, 384-388, 1997.
11. Xu, X., Fu, X.Y., Plate, J. and Chong, A.S. : IFN-gammma induces cell growth inhibition by Fasmediated apoptosis : requirement of STAT1 protein for up-regulation of Fas and FasL expression. Cancer Res., 58, 2832-2837, 1998.
12. Niehans, G.A., Brunner, T., Frizelle, S.P., Liston, J. C., Salerno, C.T., Knapp, D.J., Freen, D.R. and Kratzke, R. A. : Human lung carcinomas express Fas ligand. Cancer Res., 57, 1007-1012, 1997.
13. O'Connell, J., O'Sullivan, G.C., Collins, J.K. and Shanahan, F. : The Fas counterattack : Fas-mediated T cell killing by coton cancer cells expressing Fas ligand. J.Exp. Med., 184, 1075-1082, 1996.
14. Strand, S., Hofmann, W.J., Hug, H., Muller, M., Otto, G., Strand, D., Mariani, S.M., Stremmel, W., Krammer, P.H. and Galle, P.R. : Lymphocyte apoptosis induced by CD95 (APO-1 Fas) Ligand-expressing tumor cells - A mechanism of immune evasion? Nat. Med., 2, 1361-1366, 1996.
15. Hahne, M., Rimoldi, D., Schroter, M., Romero, P., Schreier, M., French, L.E., Schneider, P., Bornaud, T., Fontana, A., Lienard, D., Cerottini, J-C. and Tschopp, J. : Melanoma cell expression of Fas (APO-1/CD95) ligand : Implications for tumor immune escape Science ( Washington DC ). 274. 1363-1366, 1996.
16. Bellgrau, D., Gold, D., Selawry, H., Moore, J., Franzusoff, A. and Duke, R.C. : A role for CD95 Ugand in preventing graft rejection. Nature (Lond) , 377, 630-632, 1995.
17. Griffith, T.S., Brunner, T., Fletcher, S.M., Green, D. R. and Ferguson, T.A. : Fas ligand-induced apoptosis as a mechanism of immune privilege. Science (Washington DC), 270, 1189-1192, 1995.